Lily L. Remsing Rix

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

Uwe Rix, Oliver Hantschel, Gerhard Dürnberger et al. · Blood · 2007 · 663 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

Lily L. Remsing Rix, Uwe Rix, Jacques Colinge et al. · Leukemia · 2008 · 279 citations · Full text

Medicine, Oncology, Pharmacology +16

Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells

Jae‐Young Kim, Eric A. Welsh, Umut Oguz et al. · Proceedings of the National Academy of Sciences · 2013 · 123 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +15

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets

Claire E. Knezevic, Gabriëla Wright, Lily L. Remsing Rix et al. · Cell chemical biology · 2016 · 102 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +12

Polypharmacology-based ceritinib repurposing using integrated functional proteomics

Brent M. Kuenzi, Lily L. Remsing Rix, Paul A. Stewart et al. · Nature Chemical Biology · 2017 · 96 citations · Full text

Life Sciences, Molecular Biology, Molecular Medicine +14